Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint pathways has led to a rapidly expanding repertoire of immune checkpoint inhibitors for the treatment of various cancers. The app...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinh, Saralinh, Le, Alex, Gowani, Sajida, La-Beck, Ninh M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371672/
https://www.ncbi.nlm.nih.gov/pubmed/30931360
http://dx.doi.org/10.4103/apjon.apjon_3_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371672/
https://www.ncbi.nlm.nih.gov/pubmed/30931360
http://dx.doi.org/10.4103/apjon.apjon_3_19

Ejemplares similares